Patents Assigned to Thomas Jefferson University
  • Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
    Patent number: 10533054
    Abstract: Provided is a fusion protein comprising an agonist for CD40 and an agonist for OX40. Compositions comprising the fusion protein and methods of use are also provided.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: January 14, 2020
    Assignee: Thomas Jefferson University
    Inventors: Mark L. Tykocinski, Matthew Charles Weber
  • Method for Determining the Effectiveness of Treatment for the Prevention of Heartworm Disease
    Publication number: 20200011856
    Abstract: The following discloses a novel model for parasitic worm infection, which is useful for screening for and evaluating the efficacy of antiparasitic agents. In particular, the disclosure provides an immunocompromised mouse model that, for the first time, supports advanced development of Dirofilaria immitis (Di) parasites outside of their definitive hosts. As described herein, early-stage larval forms of Di, the causative agent of Canine Heartworm disease, not only persist in this model, but they develop into mature worms.
    Type: Application
    Filed: February 8, 2018
    Publication date: January 9, 2020
    Applicants: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC., THOMAS JEFFERSON UNIVERSITY
    Inventors: Brenda BONDESEN, John Matthew HARRINGTON, David ABRAHAM, Jessica HESS
  • Treatment and prevention of thrombosis using an anti-miR
    Patent number: 10517888
    Abstract: Disclosed are anti-miR compositions and methods of use of the same for treatment of or reducing the occurrence of thrombosis and thrombosis related diseases and disorders by reducing platelet activation.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: December 31, 2019
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: Steven E. McKenzie, Yuhang Zhou, Shaji Abraham
  • Engineered antibody for inhibition of fibrosis
    Patent number: 10501533
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: December 10, 2019
    Assignee: Thomas Jefferson University
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE
    Publication number: 20190365794
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Application
    Filed: July 22, 2019
    Publication date: December 5, 2019
    Applicant: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Nanocomposite hemp
    Patent number: 10494501
    Abstract: A composite material comprising a polymer and a carbonized hemp filler, wherein the carbonized hemp filler is produced by carbonizing hemp at a temperature of at least 1100 C to produce a char; and milling the char to produce a particle size, wherein the filler comprises 95% of particles of less than 10 microns in size; and wherein the hemp filler comprises between 1 and 50% of the total mass of the composite.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: December 3, 2019
    Assignee: Thomas Jefferson University
    Inventor: Ronald Kander
  • Antibiotic drug release sheath
    Patent number: 10485902
    Abstract: An implantable medical device having a sheath formed of a polymer material, wherein the sheath forms a reservoir attached to or around the implantable medical device, and wherein the reservoir is sealed with a biocompatible pressure responsive coating; wherein the biocompatible coating is stable for at least 7-day post implantation into a body, and can be mechanically ruptured by application of an exterior pressure generating force.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: November 26, 2019
    Assignees: Thomas Jefferson University, Drexel University
    Inventors: Christopher K. Kepler, Alex Michael Sevit, Steven Michael Kurtz, Noreen J. Hickok, Flemming Forsberg, John R. Eisenbrey
  • HEAD NECK IMMOBILIZATION WRAP
    Publication number: 20190351255
    Abstract: An immobilization apparatus having at least one or more straps that engage a surface; wherein at least one of the straps comprises a force gauge to determine the amount of force applied to a patient immobilized with said straps; wherein the position of the patient is replicable for treatment of radiation and other head or neck treatments.
    Type: Application
    Filed: January 22, 2018
    Publication date: November 21, 2019
    Applicant: Thomas Jefferson University
    Inventors: Hyun Kim, Voichita Bar Ad, Amy Taylor, Shivank Garg
  • SIGNAL PROCESSING METHOD FOR DISTINGUISHING AND CHARACTERIZING HIGH-FREQUENCY OSCILLATIONS
    Publication number: 20190307345
    Abstract: A device and a signal processing method that can be used with a device to recognize and distinguish a physiological high-frequency oscillation (HFO) from a pathological high-frequency oscillation. The signal processing method detects a physiological HFO in the electrical brain signal one regimen of electrical or optogenetic brain stimulation can be triggered, alternatively if the method detects a pathological HFO associated with epilepsy a different regimen of electrical or optogenetic brain stimulation can be triggered. Thus, the signal processing method can be utilized in a closed loop brain stimulation device that serves the dual purpose of both enhancing memory encoding, consolidation, and recall, or improving cognition, and reducing the probability of a seizure in a patient with epilepsy.
    Type: Application
    Filed: December 4, 2017
    Publication date: October 10, 2019
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Shennan Weiss, Zachary Waldman, Inkyung Song
  • Tumor-selective CTLA-4 antagonists
    Patent number: 10414814
    Abstract: Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 17, 2019
    Assignees: City of Hope, Thomas Jefferson University
    Inventors: John C. Williams, Ulrich Rodeck, Kurt Jenkins
  • Implantable vital sign sensor
    Patent number: 10413200
    Abstract: An implantable vital sign sensor including a housing including a first portion, the first portion defining a first open end, a second open end opposite the first end, and a lumen there through, the first portion being sized to be implanted substantially entirely within the blood vessel wall of the patient. A sensor module configured to measure a blood vessel blood pressure waveform is included, the sensor module having a proximal portion and a distal portion, the distal portion being insertable within the lumen and the proximal portion extending outward from the first open end.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: September 17, 2019
    Assignee: Thomas Jefferson University
    Inventor: Jeffrey I Joseph
  • INHIBITING MICRORNA TO PREVENT DEVELOPMENT OF ESSENTIAL HYPERTENSION
    Publication number: 20190264212
    Abstract: Therapeutic compositions and methods of treatment of the central nervous system, specifically towards hypertension comprising administration of a therapeutic comprising an anti-miR-135a, an anti-miR-miR-376a, or a combination, in the central nervous system effectively attenuates hypertension for up to four weeks provided a single administration.
    Type: Application
    Filed: July 20, 2017
    Publication date: August 29, 2019
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Rajanikanth Vadigepalli, Danielle Decicco, James Schwaber
  • LEVERAGING THE PRESENCE OR ABSENCE OF MIRNA ISOFORMS FOR RECOMMENDING THERAPY IN CANCER PATIENTS
    Publication number: 20190249262
    Abstract: A method of identifying a subject in need of therapeutic intervention to treat a disease or condi-tion or disease recurrence or disease progression comprising, isolating isomiRs or miRNAs from a sample obtained from the subject; and characterizing the isomiRs or miRNAs and their presence or absence in the sample to identify a signature, wherein when the signature is indicative of a di-agnosis of the disease then treatment of the subject is recommended.
    Type: Application
    Filed: October 23, 2017
    Publication date: August 15, 2019
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Isidore Rigoutsos, Aristeidis G. Telonis
  • PD-L1 and PD-L2-based fusion proteins and uses thereof
    Patent number: 10364279
    Abstract: Provided are fusion proteins comprising a first domain and a second domain, wherein the first domain comprises a polypeptide that binds to and triggers PD-1 and the second domain comprises a polypeptide that binds to and triggers a TRAIL receptor or Fas. In some embodiments, the polypeptide that binds to and triggers PD-1 comprises at least a portion of the extracellular domain of PD-L1 or PD-L2 and the second domain comprises at least a portion of the extracellular domain of TRAIL or Fas ligand. Also provided are methods for treating autoimmune, alloimmune or inflammatory diseases, and methods for treating cancer, using the fusion proteins.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 30, 2019
    Assignee: Thomas Jefferson University
    Inventor: Mark L. Tykocinski
  • Development of masked therapeutic antibodies to limit off-target effects
    Patent number: 10357571
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: July 23, 2019
    Assignees: Thomas Jefferson University, City of Hope
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • Methods and compositions for treating cancers using antisense
    Patent number: 10357509
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: July 23, 2019
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION
    Publication number: 20190201420
    Abstract: The present disclosure relates to methods of affecting platelet activation by the use of a PC-TP inhibitor. The PC-TP inhibitor can be administered to a subject in need thereof in order to prevent or treat pathologic thrombosis, or to treat a disorder treatable by a PAR4 inhibitor.
    Type: Application
    Filed: August 1, 2017
    Publication date: July 4, 2019
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Paul F. Bray, Michael Holinstat
  • Implantable vital sign sensor
    Patent number: 10335043
    Abstract: An implantable vital sign sensor including a housing including a first portion, the first portion defining a first open end, a second open end opposite the first end, and a lumen there through, the first portion being sized to be implanted substantially entirely within the blood vessel wall of the patient. A sensor module configured to measure a blood vessel blood pressure waveform is included, the sensor module having a proximal portion and a distal portion, the distal portion being insertable within the lumen and the proximal portion extending outward from the first open end.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: July 2, 2019
    Assignee: Thomas Jefferson University
    Inventors: Apurva Jain, Jeffrey I. Joseph, Nance Dicciani, Denise Devine, David Demmer
  • NOVEL METHODS OF TREATING A NEURODEGENERATIVE DISEASE IN A MAMMAL IN NEED THEREOF
    Publication number: 20190192503
    Abstract: The present invention provides a method of treating or ameliorating a neurodegenerative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ABC transporter inhibitor, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated in the mammal. In certain embodiments, the neurodegenerative disease comprises at least one selected from the group consisting of spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, a tauopathy, and chronic traumatic encephalopathy.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: Thomas Jefferson University
    Inventors: Davide Trotti, Piera Pasinelli, Michael R. Jablonski
  • CTLA4-BINDING PROTEIN PEPTIDE-LINKER MASKS
    Publication number: 20190169245
    Abstract: Provided herein are recombinant CTLA-4 binding proteins, which are, inter alia, useful for the treatment of cancer. The recombinant proteins provided herein are, inter alia, capable of binding CTLA-4 proteins on a tumor cell. In a first aspect, there is provided a recombinant CTLA-4 binding protein including (i) a CTLA-4 binding domain; (ii) a CTLA-4 binding domain masking peptide; and (iii) a cleavable peptide linker connecting the CTLA-4 binding domain masking peptide to the CTLA-4 binding domain. In another aspect, there is provided a dimerizing domain covalently attached to the CTLA-4 binding domain, wherein the binding protein domains are bound together.
    Type: Application
    Filed: January 13, 2016
    Publication date: June 6, 2019
    Applicants: City of Hope, Thomas Jefferson University and Health System, Innovation Pillar
    Inventors: John WILLIAMS, Ulrich RODECK